• Significant increase in total revenues from ordinary activities of 345%
• Net loss of $2.97 million, primarily due to share-based payments and increased operating costs
• Progressed key pilot projects with PNS and Life Radiology, expanding commercial pipeline

Singular Health Group Ltd reported a 345% increase in total revenues from ordinary activities for the half-year ended 31 December 2025, though net loss increased to $2.97 million, up 55% from the prior corresponding period. The losses were primarily attributable to a $1.01 million share-based payment expense and increased operating costs associated with the progression of regulatory, product development, and commercialisation initiatives for the 3DICOM® platform, as well as higher personnel expenses from strategic hires. The company made tangible advancements across clinical deployments, product development, regulatory compliance, and market engagement, particularly in the United States. This included the progression of the PNS contract deployment, the Life Radiology pilot, and the submission of a confidential multimillion dollar project request to the Florida House of Representatives. Singular Health also formally established its U.S. subsidiary, Singular Health Group USA LLC, and appointed a Chief Commercial Officer - U.S. to lead its national rollout efforts. Subsequent to the reporting period, the company achieved a major regulatory milestone with the receipt of FDA 510(k) clearance for its 3DICOM MD® Cloud platform, which expands the range of supported imaging modalities and enables rapid, low-friction deployment across clinical teams and sites.

Singular Health remains well positioned to capitalize on its strategic growth agenda in 2026 and beyond, with the FDA clearance for 3DICOM MD® Cloud expected to drive broader adoption across health systems, imaging networks, and managed care organizations seeking scalable, interoperable imaging solutions.